G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: Evidence for clinical benefits and reduction of treatment costs

Bone Marrow Transplantation

Volumn 21, Issue 4, 1998, Pages 401-407

  Tarella, C ^a,e   Castellino, C ^a   Locatelli, F ^b   Caracciolo, D ^a   Corradini, P ^a   Falda, M ^b   Novarino, A ^c   Tassi, V ^d   Pileri, A ^a  

^a Dipto di Med e Oncol Sperimentale Div Universitaria di Ematologia   (Italy)

^b Div Osped Ematologia

^c Clinica Medica I

^d Banca del Sangue   (Italy)

^e Cattedra di Ematologia   (Italy)

Author keywords

Economic evaluation; G CSF; PBPC autograft; Post graft recovery

Indexed keywords

ANTIBIOTIC AGENT; CD34 ANTIGEN; MELPHALAN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; FEMALE; FEVER; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MALE; MORBIDITY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

EID: 0031890366     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701104     Document Type: Article

References (42)

1. Brandt SJ, Peters WP, Atwater SK et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. New Engl J Med 1988; 318: 869-876.
2. Kodo H, Tajika K, Takahashi S et al. Acceleration of neutrophilic granulocyte recovery after bone marrow transplantation by administration of recombinant human granulocyte colony-stimulating factor. Lancet 1988; ii: 38-39.
3. Sheridan WP, Morstyn G, Wolf M et al. Granulocyte-colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1988; ii: 891-895.
4. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl J Med 1991; 324: 1773-1778.
5. Rabinowe SN, Nemunaitis J, Armitage J et al. The impact of myeloid growth factors on engraftment following autologous bone marrow transplantation for malignant lymphoma. Semin Hematol 1991; 28: 6-16.
6. Khwaja A, Linch DC, Goldstone AH et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplant for malignant lymphoma: a British National Lymphoma investigation double-blind, placebo-controlled trial. Br J Haematol 1992; 82: 317-323.
7. Stahel RA, Jost LM, Cerny T et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malginancies. J Clin Oncol 1994; 12: 1931-1938.
8. Advani R, Chao NJ, Horning SJ et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992; 16: 183-189.
9. Shimazaki C, Oku N, Uchiyama H et al. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1994; 13: 271-275.
10. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661-670.
11. Bolwell BJ, Goormastic M, Yanssens T et al. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant 1994; 14: 913-918.
12. Cortelazzo S, Viero P, Bellavita P et al. Granulocyte colonystimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 935-941.
13. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factors accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-1327.
14. Legros M, Fleury J, Bay JO et al. rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial. Bone Marrow Transplant 1997; 19: 209-213.
15. McQuaker IG, Hunter AE, Pacey S et al. Low-dose Filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and ecomonic benefits. J Clin Oncol 1997; 15: 451-457.
16. Gianni AM, Bregni M, Siena S et al. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high-dose chemo-radiotherapy? Hematol Oncol 1989; 7: 139-148.
17. Gianni AM, Siena S, Bregni M et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 1989; ii: 580-585.
18. Sheridan WP, Begley CG, Juttner C et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; i: 640-644.
19. Brugger W, Birken R, Bertz H et al. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte colony-stimulating factor accelerated both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol 1993; 84: 402-407.
20. Haas R, Mohle R, Frahauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3894.
21. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collection in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
22. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86: 3970-3978.
23. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New Engl Med 1997; 336: 1290-1295.
24. Tarella C, Gavarotti P, Caracciolo D et al. Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rate in poor risk lymphomas. Ann Oncol 1995; 6 (Suppl. 4) 3-8.
25. Weinstein HJ, Cassady JR, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin (adriamycin), and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1983; 1: 537-541.
26. Velasquez WS, Cabanillas F, Salvador P et al. Effect salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 1988; 71: 177-122.
27. Tarella C, Caracciolo D, Gavarotti P et al. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. Bone Marrow Transplant 1995; 16: 223-228.
28. Caracciolo D, Gavarotti P, Aglietta M et al. High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1993; 12: 621-625.
29. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
30. Tarella C, Ferrero D, Bregni M et al. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer 1991; 27: 22-27.
31. Mulder POM, Sleijfer DT, Willemse PHB et al. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 1989; 49: 4654-4658.
32. Tarella C, Benedetti G, Caracciolo D et al. Both early and committed haematopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. Br J Haematol 1995; 91: 535-543.
33. Carlo Stella C, Cazzola M, De Fabritiis P et al. CD34-positive cells: biology and clinical relevance. Haematologica 1995; 80: 367-387.
34. Hohaus S, Goldschmidt H, Ehrhardt R et al. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rh-G-CSF. Exp Hematol 1993; 21: 508-514.
35. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
36. Kawano Y, Takaue Y, Watanabe T et al. Effect of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children. Exp Hematol 1993; 21: 103-108.
37. Siena S, Bregni M, Di Nicola M et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994; 5: 935-941.
38. Ikebuchi K, Clark SC, Ihle JN et al. Granulocyte colony-stimulating factor inhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad USA 1988; 85: 3445-3449.
39. Hogge DE, Cashman JD, Humphries RK et al. Differential and synergistic effects of human granulocyte-macrophage colony-stimulating factor and human granulocyte colony-stimulating factor on hematopoiesis in human long-term marrow culture. Blood 1991; 77: 493-499.
40. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effective-ness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis awaiting clinical trial results. JAMA 1992; 267: 2055-2061.
41. Gulati SC, Bennet CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992; 116: 177-182.
42. Uyl-de Groot CA, Hagenbeek A, Verdonck LF et al. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate-and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 1995; 16: 463-470.